PLX-61639

PLX-61639 is a selective, oral small molecule molecular glue degrader developed by Plexium for the treatment of solid tumors. It targets SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), a component of the chromatin remodeling BAF complex that regulates gene expression. Functional genomic screens in cancer cell lines have shown a synthetic lethal relationship between SMARCA2 and SMARCA4, making inhibition or degradation of SMARCA2 a promising strategy in cancers with loss or mutation of SMARCA4. The drug is currently in preclinical and discovery stages for indications such as non-small cell lung cancer and other solid tumors[1][2][3].

Other names

SMARCA2 (Plexium)